Clinical Trials Update: May 17, 2005
Serial Evaluation of Ductal Epithelium Colorectal Cancer HIV
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
Serial Evaluation of Ductal Epithelium
Since breast cancer can occur in the breast milk duct lining, this study will obtain breast duct cells from each participant using the technique of ductal lavage every six months for three years.
Women at high risk for breast cancer are eligible for participation in this research study. You are eligible if you are between 35 and 70, have intact nipples, have had a family history of breast cancer, and will be available for five years for continuing studies.
The research site is in Milwaukee.
This study is designed to assess whether treatment with panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared to treatment with Q2-week oxaliplatin-based chemotherapy and bevacizumab alone.
Men and women 18 or older are eligible to participate.
The research site is in Fountain Valley, Calif.
Atherosclerosis is a slowly progressive disease where there is accumulation of cholesterol within the blood vessel wall.
This is a four-week trial of Provigil.
This medication is approved by the FDA to treat excessive daytime sleepiness. It is being investigated for use in HIV-related fatigue.
Qualifications are HIV positive men and women with persistent fatigue that interferes with daily activities. Certain medical restrictions apply.
The research site is in New York City.
Copyright 2005 CenterWatch. All rights reserved.